Corrigendum

Corrigendum to “Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV”

Simona Di Mario,1 Vittorio Basevi,1 Pier Luigi Lopalco,2 Sara Balduzzi,3 Roberto D’Amico,3 and Nicola Magrini4

1SaPeRiDoc Unit, Department of Primary Health Care, Regional Health Authority of Emilia-Romagna, Viale Aldo Moro 21, 40127 Bologna, Italy
2Office of Chief Scientist, European Centre for Disease Prevention and Control (ECDC), 171 83 Stockholm, Sweden
3Statistics Unit, Department of Diagnostic and Clinical Medicine and Public Health, University of Modena & Reggio Emilia, Via del Pozzo 71, 41100 Modena, Italy
4Drug Evaluation Unit, WHO Collaborating Centre for Evidence Based Research Synthesis and Guidelines Development, Regional Health and Social Agency of Emilia-Romagna, Viale Aldo Moro 21, 40127 Bologna, Italy

Correspondence should be addressed to Simona Di Mario; sdimario@regione.emilia-romagna.it

Received 5 April 2017; Accepted 10 April 2017; Published 30 May 2017

Copyright © 2017 Simona Di Mario et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV” [1], there was an error in the Discussion section, where “Our systematic review highlights that, for precancerous lesions (CIN), the only available proxy of cervical cancer and heterogeneity among pooled studies is substantial” should be changed to “Our systematic review highlights that, for precancerous lesions (CIN), the only available proxy of cervical cancer, heterogeneity among pooled studies is substantial.” In addition, there was an error in Table 3. The corrected table is as follows.
<table>
<thead>
<tr>
<th>Study</th>
<th>Age mean (SD)</th>
<th>HPV 16 positivity at enrolment (%) DNA Serology</th>
<th>HPV 18 positivity at enrolment (%) DNA Serology</th>
<th>Lifetime number of sexual partners (median)</th>
<th>Smoking status (%)</th>
<th>Chlamydia trachomatis (%)</th>
<th>Hormonal contraceptive use (%)</th>
<th>Cytological abnormality at entry (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GSK [11, 12, 28]</td>
<td>20 ± 3</td>
<td>VNR</td>
<td>CVR</td>
<td>VNR</td>
<td>0* 4%</td>
<td>0* 4%</td>
<td>0* 4%</td>
<td>0* 4%</td>
</tr>
<tr>
<td>PATRICIA [13, 27]</td>
<td>20 ± 3</td>
<td>6 5 17 17</td>
<td>2 2 12 12</td>
<td>6 5</td>
<td>74% 74%</td>
<td>14% 15%</td>
<td>8% 8%</td>
<td>12 11</td>
</tr>
<tr>
<td>FUTURE I [16, 26, 30]</td>
<td>20 ± 2</td>
<td>9 8 12 12</td>
<td>3 3 3 3</td>
<td>2 2</td>
<td>26 26</td>
<td>58 57</td>
<td>11 12</td>
<td></td>
</tr>
<tr>
<td>FUTURE II [17, 26, 30]</td>
<td>20 ± 2</td>
<td>9 9 11 11</td>
<td>4 4 4 4</td>
<td>4 4</td>
<td>NR 4</td>
<td>59 60</td>
<td>12 11</td>
<td></td>
</tr>
</tbody>
</table>

V: vaccine group; C: control group; NR: not reported. *Results are presented as percentage of women stratified by number of sexual partners.

Table 3: Baseline characteristics of women enrolled in the four studies presented in the meta-analysis.
References
